ImmunityBio and EnGeneIC to advance nanocell tech for cancer treatment and Covid-19 vaccine

Date Published11/30/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name EnGeneIC
Type of work Manufacturing
If manufacturing, is the company a contract manufacturer?Yes
Reshoring category:Foreign Direct Investment
Year reshoring announced:2021
Domestically, the work will be done:Outsourced
Country(ies) from which reshored:Australia
If relevant, work nearshored to:-
Product(s) reshoredEnGeneIC Dream Vector (EDV), non-living nanocells
What domestic positive factors made reshoring more attractive?Other, Covid-19
Find Reshoring Articles